| Autor: |
Biberoğlu S; Department of Emergency Medicine, Cerrahpasa Faculty of Medicine, Istanbul University Cerrahpasa, Istanbul, Turkey., İpekci A; Department of Emergency Medicine, Cerrahpasa Faculty of Medicine, Istanbul University Cerrahpasa, Istanbul, Turkey., İkizceli İ; Department of Emergency Medicine, Cerrahpasa Faculty of Medicine, Istanbul University Cerrahpasa, Istanbul, Turkey., Çakmak F; Department of Emergency Medicine, Cerrahpasa Faculty of Medicine, Istanbul University Cerrahpasa, Istanbul, Turkey., Akdeniz YS; Department of Emergency Medicine, Cerrahpasa Faculty of Medicine, Istanbul University Cerrahpasa, Istanbul, Turkey., Kanbakan A; Department of Emergency Medicine, Yuksekova State Hospital, Hakkari, Turkey., Konukoğlu D; Department of Medical Biochemistry, Cerrahpasa Faculty of Medicine, Istanbul University Cerrahpasa, Istanbul, Turkey., Bolayırlı İM; Department of Medical Biochemistry, Cerrahpasa Faculty of Medicine, Istanbul University Cerrahpasa, Istanbul, Turkey., Börekçi Ş; Department of Pulmonology, Cerrahpasa Faculty of Medicine, Istanbul University Cerrahpasa, Istanbul, Turkey., Ürkmez S; Department of Intensive Care (Anesthesia & Reanimation), Cerrahpasa Faculty of Medicine, Istanbul University Cerrahpasa, Istanbul, Turkey., Özkan S; Department of Emergency Medicine, Cerrahpasa Faculty of Medicine, Istanbul University Cerrahpasa, Istanbul, Turkey. |
| Abstrakt: |
Introduction: SARS-CoV-2 requires angiotensin-converting enzyme 2 (ACE2) to enter the cell. In our study, we aimed to investigate the role of angiotensin-converting enzyme 2 and angiotensin II plasma levels on prognosis and mortality in patients with isolated hypertension, patients with chronic diseases in addition to hypertension and patients with COVID-19 without comorbidities, in accordance with the use of renin-angiotensin-aldosterone system inhibitor. Materials & methods: In the study, patients diagnosed with COVID-19 were divided into three groups. Angiotensin II and ACE2 levels were compared by comorbidities, antihypertensive drugs used, intensive care hospitalization and termination of patients. The relationship between angiotensin II and ACE2 levels and service and intensive care times was investigated. Findings: A total of 218 patients were enrolled in our study, including 68 patients diagnosed with COVID-19 without comorbidities, 33 patients diagnosed with isolated hypertension and 117 patients with other chronic diseases in addition to hypertension. There was no statistically significant difference between the comorbid disease groups between angiotensin II and ACE2 levels of the patients enrolled in the study. The rate of patients admitted to the intensive care unit was 17.9%, and the mortality rate was 11.5%. Results: In our study, we did not obtain significant findings regarding angiotensin II and ACE2 levels on presentation that can be used in prognosis and mortality of COVID-19 patients and development of future treatment methods. |
